Table 2.
Overview of studies reporting NICE Composite endpoint in real-world evidence studies
| Code | Intervention | Mean baseline HbA1c (SD), % | N | Follow-up duration (months) | NICE composite endpointb achieved |
|---|---|---|---|---|---|
| Full-text publications | |||||
| Nyeland et al. 2015 [58] | Liraglutide | 8.8 (1.9) | 287 | 6 | 25.10% |
| Sitagliptin | 8.6 (1.5) | 2781 | 10.4%a | ||
| Heymann et al. 2014 [51] | Liraglutide | 9.7 (NA) | 1101 | 6 | 20.10% |
| Russo et al. 2015 [44] | Liraglutide | 8.2 (1.3) | 115 | 12 | 47% |
| Evans et al. 2014 [33] | Liraglutide | 9.6 (0.5) | 229 | 12 | 32% |
| Exenatide | 9.8 (0.8) | 148 | 24% | ||
| DPP-4i | 8.1 (0.4) | 710 | 64% | ||
| Evans et al. 2013 [32] | Exenatide BID | 9.6 (0.5) | 148 | 12 |
3 months: 27% 6 months: 24% 9 months: 26% 12 months: 25% Audit end: 21% |
| Liraglutide | 9.8 (0.8) | 256 |
3 months: 35% 6 months: 32% 9 months: 31% 12 months: 29% Audit end: 28% |
||
| DPP-4i (sitagliptin, saxagliptin, or vildagliptin) | 8.1(0.4) | 710 |
3 months: 59% 6 months: 61% 9 months: 52% 12 months: 54% Audit end: 57% |
||
| Conference abstracts | |||||
| Heymann et al. 2013 [80] | Liraglutide | 8.7 (1.3) | 453 | 6 | 20.10% |
| Karasik et al. 2013 [81] | Liraglutide | 8.57 (1.20) | 614 | 6 | 16.90% |
| Fatima et al. 2014 [82] | Liraglutide | 8.7 (NA) | 43 | 6 | 42% |
| Mattson et al. 2015 [79] | Liraglutide | 7.69 (1.43) | 180 | 6 | 27% |
| Sitagliptin | 7.53 (1.50) | 208 | 10% | ||
BID twice daily, DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycated hemoglobin, N number of patients, NA not available, NICE National Institute for Health and Care Excellence, SD standard deviation
a P < 0.001
bPercentage of patients with HbA1c reduction ≥1% and weight reduction ≥3%